The latest announcement is out from ADC Therapeutics Ltd (ADCT).
The Company recently released a presentation revealing promising initial results from a Phase 2 clinical trial for ZYNLONTA in treating patients with relapsed or refractory marginal zone lymphoma. This information, while not “filed” under SEC regulations, offers exciting insights, potentially impacting the company’s stock as investors and market watchers evaluate these new developments in its clinical advancements.
See more insights into ADCT stock on TipRanks’ Stock Analysis page.
